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Lytic replication of Kaposi's sarcoma-associated herpesvirus (KSHV) promotes the progression of Kaposi's sarcoma (KS), a dominant
malignancy in patients with AIDS. While 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced KSHV reactivation from latency is mediated by
the protein kinase C δ and MEK/ERK mitogen-activated protein kinase (MAPK) pathways, we have recently shown that the MEK/ERK, JNK and
p38 MAPK pathways modulate KSHV lytic replication during productive primary infection of human umbilical vein endothelial cells [Pan, H.,
Xie, J., Ye, F., Gao, S.J., 2006. Modulation of Kaposi's sarcoma–associated herpesvirus infection and replication by MEK/ERK, JNK, and p38
multiple mitogen–activated protein kinase pathways during primary infection. J. Virol. 80 (11), 5371–5382]. Here, we report that, besides the
MEK/ERK pathway, the JNK and p38 MAPK pathways also mediate TPA-induced KSHV reactivation from latency. The MEK/ERK, JNK and
p38 MAPK pathways were constitutively activated in latent KSHV-infected BCBL-1 cells. TPA treatment enhanced the levels of activated ERK
and p38 but not those of activated JNK. Inhibitors of all three MAPK pathways reduced TPA-induced production of KSHV infectious virions in
BCBL-1 cells in a dose-dependent fashion. The inhibitors blocked KSHV lytic replication at the early stage(s) of reactivation, and reduced the
expression of viral lytic genes including RTA, a key immediate-early transactivator of viral lytic replication. Activation of MAPK pathways was
necessary and sufficient for activating the promoter of RTA. Furthermore, we showed that the activation of RTA promoter by MAPK pathways
was mediated by their downstream target AP-1. Together, these findings suggest that MAPK pathways might have general roles in regulating the
life cycle of KSHV by mediating both viral infection and switch from viral latency to lytic replication.
© 2007 Elsevier Inc. All rights reserved.Keywords: Kaposi's sarcoma; KSHV; Reactivation; MAPK pathways; AP-1; RTA; TPA⁎ Corresponding author. Tumor Virology Program, Greehey Children's Cancer
Research Institute, The University of Texas Health Science Center at San Antonio,
8403 Floyd Curl Drive, San Antonio, TX 78229, USA. Fax: +1 210 562 9014.
E-mail address: gaos@uthscsa.edu (S.-J. Gao).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.09.040Introduction
Infection by Kaposi's sarcoma-associated herpesvirus
(KSHV), also known as human herpesvirus 8 (HHV8), is
linked to the development of Kaposi's sarcoma (KS), a
malignancy frequently seen in untreated AIDS patients (Greene
et al., 2007). In the last two decades, KS has evolved as the most
140 J.P. Xie et al. / Virology 371 (2008) 139–154common cancer in some African regions, and could account for
up to 30% of all types cancer in both HIV-infected and unin-
fected adult and pediatric patients (Orem et al., 2004). In these
regions, KSHV seroprevalence reaches up to 70% in the general
population (Greene et al., 2007). With the spread of the AIDS
epidemics, KSHVand KS have emerged as an important health
problem worldwide. Besides KS, KSHV is also associated with
some other malignancies such as primary effusion lymphoma
(PEL) and multicentric Castleman's disease (Greene et al.,
2007).
Like other herpesviruses, the life cycle of KSHV consists of
two phases: a latent phase during which the virus persists as
episomes expressing several viral latent genes; and a lytic phase
during which the viral genomes replicate in a linear form
expressing most of the more than 80 viral lytic genes, and
produces infectious virions (Dourmishev et al., 2003). In KS
lesions, the majority of tumor cells are latently infected by
KSHV, indicating an essential role for viral latent infection in
tumor development (Dupin et al., 1999); however, a small
number of KS tumor cells also undergo lytic infection (Staskus
et al., 1997; Zhong et al., 1996). Results from recent laboratory
and clinical studies have indicated that these lytic cells might
promote KS tumors through several synergetic mechanisms
including: the production of infectious virions for spreading to
new target cells, the induction of angiogenic and inflammatory
cytokines during virus spread and lytic replication, and the
generation of KSHV-encoded angiogenic and inflammatory
cytokines, and regulatory molecules (Greene et al., 2007). Thus,
it is essential to understand the mechanism controlling KSHV
lytic replication.
So far KSHV lytic replication has been examined primarily
with cell lines isolated from lymphomas or peripheral blood
mononuclear cells of PEL patients (Cesarman et al., 1995; Gao
et al., 1996b; Renne et al., 1996). These cells are latently infected
by KSHV but can be reactivated into lytic replication by
chemical inducers such as 12-O-tetradecanoyl-phorbol-13-
acetate (TPA). These studies have identified the protein of
replication and transcriptional activator (RTA) encoded by
ORF50 as a central viral protein that controls KSHV lytic
replication (Lukac et al., 1998; Sun et al., 1998; Xu et al., 2005).
The expression of RTA leads to the transactivation of cascades of
viral lytic genes and the replication of viral genomes, which
results in full viral lytic replication. Consequently, RTA is
necessary and sufficient for activating KSHV from latency
(Lukac et al., 1998; Sun et al., 1998; Xu et al., 2005).
Multiple factors control the expression of RTA and KSHV
lytic replication. Both epigenetic modifications and cellular
signaling pathways play important roles in regulating the ex-
pression of RTA. The RTA promoter is associated with histone
deacetylases 1, 5, and 7 in latent PEL cells (Lu et al., 2003).
Treatment with butyrate induces KSHV reactivation, which
correlates with the rapid association of Ini1/Snf5, a component
of the Swi/Snf family of the chromatin remodeling proteins.
TPA treatment leads to the demethylation of RTA promoter and
KSHV reactivation from latency (Chen et al., 2001). TPA
induction of KSHV reactivation is also mediated by calcium-
dependent calcineurin signaling and protein kinase C (PKC) δpathway (Deutsch et al., 2004; Zoeteweij et al., 2001). More
recently, it was shown that epinephrine and norepinephrine
could efficiently reactivate KSHV from latency via β-
adrenergic activation of the protein kinase A (PKA) signaling
pathway (Chang et al., 2005). The CCAAT/enhancer-binding
protein-α (C/EBPα) is induced during the early stages of KSHV
reactivation, and overexpression of C/EBPα alone is sufficient
to activate the RTA promoter in transient-cotransfection reporter
gene assays (Wang et al., 2003). Hypoxia and inflammatory
cytokines including interferon-γ and oncostatin M have been
shown to induce KSHV reactivation but the underlying mech-
anisms remain undefined (Blackbourn et al., 2000; Chang et al.,
2000; Davis et al., 2001; Mercader et al., 2000; Monini et al.,
1999). While the primary target of the Notch signaling pathway
RBP-Jκ (CSL) mediates RTA activation of KSHV lytic genes
(Liang et al., 2002), overexpression of intracellular-activated
Notch1 is sufficient to reactivate KSHV from latency in PEL
cells (Lan et al., 2006). The role of NF-κB pathway in KSHV
lytic replication remains controversial. In PEL cells, inhibition
of NF-κB led to KSHV reactivation and the expression of lytic
proteins (Brown et al., 2003); however, it was reported that NF-
κB induction was required for the production of KSHV
infectious virions in TPA-induced PEL cells (Sgarbanti et al.,
2004).
We have recently shown that KSHV activates the MEK/
ERK, JNK and p38 mitogen-activated protein kinase (MAPK)
pathways during primary infection in a productive infection
system of human umbilical vein endothelial cells (HUVEC),
and these three pathways modulate not only the early viral entry
events but also subsequent viral lytic replication (Xie et al.,
2005; Pan et al., 2006). It is believed that KSHV lytic repli-
cation during productive primary infection and reactivation
from latency share similar features. Both are involved with
similar steps and viral lytic cycle genes, and as a common
consequence, both generate infectious virions. However, the
signaling pathways controlling KSHV lytic replication and their
destinies in the two processes might differ. During primary
infection, the viral genomes are newly delivered into the cells
without being subjected to epigenetic modifications. At the
same time, KSHV alters cellular pathways such as MAPK
pathways, some of which could determine whether the virus
goes into latency or lytic replication in a cell. In contrast, during
KSHV reactivation, the latent genomes are epigenetically
modified, and could respond differently to cellular signals or
cues. In spite of the differences of the two systems, the findings
from the productive primary infection system indicate that
KSHV reactivation from latency might also be modulated by the
MEK/ERK, JNK and p38 MAPK pathways (Pan et al., 2006).
Indeed, two recent studies have shown that KSHV reactivation
from latency is modulated by the MEK/ERK pathways (Cohen
et al., 2006; Ford et al., 2006). In this report, we show that
KSHV reactivation from latency is modulated not only by the
MEK/ERK pathway but also by the JNK and p38 pathways. We
further show that all three MAPK pathways mediate KSHV
reactivation through AP-1, which binds to the promoter of RTA
leading to its expression and activation of the KSHV lytic
replication program.
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Activation of ERK, JNK and p38 MAPK pathways in BCBL-1
cells
We used BCBL-1 cells infected with a recombinant KSHV,
BAC36, to define the roles of MAPK pathways in KSHV
reactivation (Zhou et al., 2002). BAC36 contains a GFP marker,
which facilitates the titration of infectious virions (Gao et al.,
2003). We first determined the status of the ERK, JNK and
p38 MAPK pathways in BCBL-1 cells. We detected robust
constitutive activation of all three pathways in BCBL-1 cells
(Fig. 1A). TPA treatment did not alter the expression levels of
total ERK, JNK and p38. Similarly, the levels of activated JNK
(pJNK) were not altered after TPA induction. In contrast, the
level of activated ERK (pERK) started to increase as early as
0.08 h post-induction (hpi) and peaked at 12 hpi (Fig. 1A). At
the peak of induction, the pERK levels in TPA-induced cells
were 3.5-fold of that of mock-induced cells (Fig. 1B). SimilarFig. 1. Constitutive activation of the ERK, JNK and p38MAPK pathways in uninduced
pathway by TPA. (A)Western-blotting with specific antibodies to detect the phosphoryla
panels), and total ERK (second set of panels), p38 (fourth set of panels) and JNK (seventh
anti-β-tubulin antibody was used to normalize the sample loading (fifth and eighth pan
were runwith another set of samples. (B)Quantification of pERK levels inmock- andTPlevels of pERK induction by TPA were previously reported
(Ford et al., 2006). After 3 day post-induction (dpi), no
difference of pERK was observed between uninduced- and
TPA-induced cells (Figs. 1A and B). Activated p38 (pp38) was
transiently and marginally induced by TPA at the early time
points (Fig. 1A). The levels of pp38 in TPA-induced cells were
1.7- and 1.6-fold of that of mocked-induced cells at 0.08 and
0.17 hpi, respectively, but dropped to similar levels afterwards
(Fig. 1C). Similar results were also observed in BCBL-1 cells
without BAC36 (data not shown), indicating that the above
observed results were not due to the presence of BAC36.
Inhibitors of MAPK pathways reduced the production of
infectious virions during TPA-induced KSHV reactivation from
latency
To determine the involvements of MAPK pathways in TPA-
induced KSHV reactivation from latency, we employed specific
pharmacological inhibitors to target the pathways: U0126 forBCBL-1 cells, and transient enhanced activation of the ERK and p38 but not JNK
ted forms of ERK (first set of panels), p38 (third set of panels) and JNK (sixth set of
set of panels) in cells inducedwith TPA for different lengths of time (0–144 h). An
els). The ERK and p38 blots were run with one set of samples while the JNK blots
A-induced cells. (C)Quantification of pp38 levels inmock- andTPA-induced cells.
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JNK inhibitor II for the JNK pathway, and SB203580 for the
p38 pathway. We induced the BCBL-1 cells with TPA for 5 day
in the presence of these inhibitors at the recommended
concentrations, i.e., 10 μM for the MEK inhibitor, and 50 μM
for the JNK and p38 inhibitors. At the end of induction, culture
supernatants were collected and titrated for the presence of
infectious KSHV virions by infecting 293 cell cultures. The
numbers of GFP-positive cells representing virus titers were
counted at 2 day post-infection. Supernatants from uninduced
cells with or without treatment with the inhibitors of MAPK
pathways had no infectious virions. As expected, we observed
high levels of infectious virions in the range of 4–5×105
GFP-positive cells/ml (GFU) in cells induced with TPA alone
(Fig. 2A). Inhibitors of all three MAPK pathways significantly
reduced virion production in TPA-induced cells as indicated
by the reduced numbers of GFP-positive cells in the titration
target 293 cultures (Fig. 2A). Quantification of the GFP-
positive cell numbers showed that the MEK, JNK and p38
inhibitors reduced virion production by 90%, 98%, and 94%,
respectively (Fig. 2B).
We had previously shown that addition of inhibitors of
MAPK pathways at the early stages of KSHV primary infection
(before 4 h post-infection) reduced virus infectivity (Pan et al.,
2006). These observations raised the issue that the reduced virus
titers in cells treated with the inhibitors of MAPK pathways
observed in Figs. 2A and B could simply be due to the effects of
the inhibitors on virus infectivity. Thus, we carried out further
investigations to define the effects of the inhibitors on KSHV
reactivation. In the primary infection study, the inhibitors were
freshly reconstituted, and immediately used for the infectivity
experiments (Pan et al., 2006). In the current study, we
performed virus titration at 5 dpi. The half-life of the inhibitors
under our current experimental conditions was unknown.
Therefore, we determined the effects of the inhibitors on
KSHV infectivity under the current experimental conditions.
We added MEK, p38, and JNK inhibitors at their working
concentrations of 10 μM, 50 μM, and 50 μM, respectively, to a
virus preparation titrated to have a titer of 5×105 GFU, and
incubated the virus preparations at 37 °C for 5 days. We then
determined the infectivity of these treated virus preparations. As
shown in Fig. 2C, all the inhibitors no longer had any effects
on KSHV infectivity. Similar results were obtained when the
virus preparations were incubated at 4 °C for 5 days with the
inhibitors (data not shown). As previously reported, addition of
freshly reconstituted inhibitors to the virus inoculum signifi-
cantly reduced KSHV infectivity (Fig. 2D). These resultsFig. 2. Inhibitors of MAPK pathways reduced the production of infectious virions in
inhibitors of MAPK pathways on TPA-induced virion production. Supernatants from
infecting 293 cells and recording GFP-positive cells at 2 days post-infection. Both JN
while U0126 (MEK inhibitor) was used at 10 μM. (B) Quantification of relative viru
described in panel A. (C, D) The effects of inhibitors of MAPK pathways on the infe
of MAPK pathways for 5 days at 37 °C before titration (C), or with freshly reconsti
inhibitors described in panel Awere used for the experiments. (E–G) Inhibitors of M
KSHVinfectious virions in a dose-dependent manner. The experiments were indepen
out twice, each with three repeats. Results presented were the averages with standaindicated that the inhibitors had lost their effectiveness after
5 days of incubation at either 37 °C or 4 °C. Thus, we concluded
that the reduction of infectious virions resulting from treatment
with the inhibitors of MAPK pathways during TPA-induced
KSHV reactivation were genuinely due to the effects of the
inhibitors on the early stages of virus reactivation rather than on
the virus infectivity in the subsequent titration experiments.
To further confirm the specificity of the inhibitors on
the production of infectious virions during KSHV reactivation,
we conducted a dose-dependent experiment. In addition, we
assayed the kinetics of virion production from 1 to 5 dpi. We
induced BCBL-1 cells with TPA in the presence of the
inhibitors at different concentrations: U0126 at 2.5, 5, 10, and
20 μM, and both JNK Inhibitor II and SB23580 at 12.5, 25,
50, and 100 μM. We collected the supernatants daily for up to
5 dpi, stored them at 4 °C, and titrated all of the supernatants
at 5 dpi. As shown in Figs. 2E–G, the production of infectious
virions increased as the time of TPA induction progressed
from 1 dpi to 5 dpi in cultures without the inhibitors. As
expected, inhibitors of all three MAPK pathways reduced
virion production in a dose-dependent fashion. At high con-
centrations of the inhibitors (20 μM for U0126, 50 and
100 μM for JNK Inhibitor II, and 100 μM for SB23580), the
production of infectious virions was totally abolished. These
results clearly demonstrated dose-dependent effects of the
inhibitors on virion production during TPA-induced KSHV
reactivation from latency.
Inhibitors of MAPK pathways targeted the early stages of
TPA-induced KSHV reactivation from latency
The above results indicated that the inhibitors of MAPK
pathways were likely to reduce virion production by affecting
the early stage(s) of KSHV reactivation as the inhibitors
appeared to have a short half-life under the experimental
condition (Fig. 2C). To further define the stage(s) of KSHV
reactivation that were modulated by the MAPK pathways, we
treated the TPA-induced BCBL-1 cells with the inhibitors of
MAPK pathways at different time points post-induction. While
addition of the inhibitors at the onset of TPA induction (0 dpi)
reduced more than 90% of virion production, addition of the
inhibitors at 1 and 2 dpi reduced the virion production at much
lower rates: 25% and 22% for the MEK inhibitor, 32% and 27%
for the JNK inhibitor, and 15% and 8% for the p38 inhibitor,
respectively (Fig. 3A). Addition of the inhibitors at 3 and 4 dpi
had only marginal or no detectable effect. To further confirm
that the inhibitors primarily exerted their effects at the earlyTPA-induced KSHV reactivation from latency in BCBL-1 cells. (A) Effects of
cells treated with the inhibitors were titrated at 5 dpi for infectious virions by
K inhibitor II (JNK inhibitor) and SB203580 (p38 inhibitor) were used at 50 μM
s titers in supernatants from cells treated with inhibitors of MAPK pathways as
ctivity of KSHV inoculums. Virus inoculums were incubated with the inhibitors
tuted inhibitors (D) immediate before titration. The same concentrations of the
EK (E), JNK (F) and p38 (G) pathways reduced the production of TPA-induced
dently carried out four times except those in panels C and Dwhich were carried
rd deviations from one experiment.
Fig. 3. Inhibitors of MAPK pathways affected the early stages of TPA-induced
KSHV reactivation from latency in BCBL-1 cells. (A) TPA-induced cells were
treated with inhibitors of MEK, JNK, and p38MAPK pathways at the onset of TPA
induction or at 1, 2, 3, and 4 dpi, and supernatants were titrated for infectious virions
at 5 dpi. (B) TPA-induced cells were treated with inhibitors of MAPK pathways at
the onset of TPA induction. Both TPA and the inhibitors were washed away at 2 dpi
and replaced with fresh medium without any inducer and inhibitors. The
supernatants were collected and titrated for infectious virions at 5 dpi. (C) TPA-
induced cells were treated with inhibitors of MEK, JNK, and p38 MAPK pathways
at the onset of TPA induction or at 2, 4, 8, 16 and 24 hpi, and the supernatants were
titrated for infectious virions at 5 dpi. All the experimentswere independently carried
out three times, each with three repeats. Results presented were the averages with
standard deviations from one representative experiment.
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TPA-induction, washed them away at 2 dpi, and titrated the
supernatants at 5 dpi. As shown in Fig. 3B, the inhibitors
effectively reduced virion production, albeit they were washed
away at 2 dpi. These results confirmed that the inhibitors
primarily targeted the early stage(s) of KSHV reactivation.To better define the stage(s) of KSHVreactivation modulated
by the MAPK pathways, we added the inhibitors at different hpi
within the first day of TPA induction (Fig. 3C). Again, addition
of the inhibitors at the onset of TPA induction (0 hpi) reduced
more than 90% of virion production. Addition of the inhibitors
at the later time points (2–16 hpi) had reduced inhibitory effects
on virion production. The later the inhibitors were added, the
less inhibitory effects were observed. At 2 hpi, their inhibitory
effects were reduced to 83%, 81% and 61% for the MEK, JNK
and p38 inhibitors, respectively. At 16 hpi, the inhibitory effects
were further reduced to 55%, 47% and 34%, respectively (Fig.
3C). Together, these results indicated that the MAPK pathways
modulated the early stage(s) of KSHV reactivation.
Inhibitors of MAPK pathways reduced the expression of viral
lytic genes during TPA-induced KSHV reactivation from latency
Efficient KSHV lytic replication depends on the expression
of viral lytic genes. During TPA-induced KSHV reactivation,
viral lytic genes are expressed in a cascade fashion with
immediate-early (IE) genes such as RTA being expressed at as
early as 6 hpi, followed by the early genes and late genes (Sun
et al., 1999). Based on the above results, we hypothesized that
inhibitors of MAPK pathways reduced the expression of viral
lytic genes to affect KSHV reactivation. Thus, we examined
the effects of the inhibitors on the expression of KSHV genes
by reverse transcription quantitative real-time PCR (RT-
qPCR). BCBL-1 cells induced with TPA with or without the
inhibitors were collected at 48 hpi and analyzed for a set of
KSHV genes representing different viral gene classes. These
included a latent gene vFLIP (ORF-K13), an IE gene RTA,
two early genes ORF59 and vIL-6 (ORF-K2), and a late gene
ORF-K8.1. TPA treatment increased the expression of vFLIP
transcripts by 3-fold and lytic transcripts by 7- to 13-fold (Fig.
4A). Inhibitors of MAPK pathways had marginal effects on the
expression of vFLIP transcripts; however, they inhibited TPA-
induction of all viral lytic genes analyzed. The expression of
RTA was reduced 80%, 77% and 57% by the MEK, JNK and
p38 inhibitors, respectively (Fig. 4A). The inhibitory effects of
the inhibitors on the expression of KSHV lytic genes are in
agreement with their inhibitory effects on the production of
infectious virions.
To confirm the effects of inhibiting MAPK pathways on the
expression of KSHV lytic transcripts, we further analyzed the
protein expression of ORF59. BCBL-1 cells induced with TPA
with or without the inhibitors of MAPK pathways were
collected at 48 hpi and analyzed for ORF59 protein expression
by immunofluorescence antibody assay (IFA) using a specific
monoclonal antibody (Fig. 4B). TPA treatment increased
ORF59-positive cells from 2.5% to 16.5% (Fig. 4C); however,
MEK, JNK and p38 inhibitors reduced ORF59-positive cells to
6.5%, 6.6% and 2.4%, respectively. In contrast, the percentage
of cells expressing KSHV major latent nuclear antigen LANA
(LNA) encoded by ORF73 was neither induced by TPA nor
reduced by the inhibitors, and remained at close to 100% (Fig.
4D). Similar results were also observed when the cells were
examined at 5 dpi (data not shown). Since LANA is the only
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replication and persistence of KSHVepisome in cells (Ballestas
et al., 1999; Ye et al., 2004), these results indicated that the
reduced levels of KSHV reactivation was not due to the loss of
KSHV genomes.
Inhibitors of MAPK pathways reduced TPA activation of the
RTA promoter
RTA is a central protein that controls KSHV reactivation.
RTA directly or indirectly activates the expression of ORF59,
vIL-6, and K8.1 (Deng et al., 2007). Since the expression of RTA
transcripts was induced by TPA but reduced by the inhibitors of
MAPK pathways, we further determined whether the RTA
promoter was modulated by MAPK pathways. First, we
examined the effect of TPA induction on the activity of the
RTA promoter. Bjab cells were transfected with a full-length
RTA promoter luciferase reporter construct, R-914. At 48 h post-
transfection, the transfected cells were assayed for luciferase
activities. Before collection, the cells were treated with TPA
for different lengths of time. As shown in Fig. 5A, TPA treat-
ment increased the activity of the RTA promoter reporter, which
peaked at around 6 hpi. At the peak of induction, TPA treatment
increased the RTA promoter reporter activity by as much as 4.8-
fold. Based on these results, we induced the cells with TPA for
6 h in the subsequent experiments.
Next, we examined the effects of modulating MAPK
pathways on the RTA promoter reporter activity. Again, Bjab
cells were transfected with the RTA promoter reporter, R-914,
and treated with TPA for 6 h with or without the inhibitors of
MAPK pathways at different concentrations. As shown in
Fig. 5B, all three inhibitors reduced TPA induction of RTA
promoter reporter activities in a dose-dependent fashion. At the
recommended working concentrations, the inhibitors of MEK,
JNK and p38 pathways (10 μM for the MEK inhibitor, and
50 μM for the JNK and p38 inhibitors) reduced the reporter
activities by 76%, 62% and 58%, respectively (Fig. 5B).
We then used dominant negative constructs (DNs) to inhibit
the MAPK pathways and assay their roles in modulating the
RTA promoter. Bjab cells were co-transfected with the RTA
promoter reporter with different concentrations of the DNs, and
assayed for luciferase activities at 48 h post-transfection. Before
cell collection, the cells were treated with TPA for 6 h. As
shown in Fig. 5C, DNs of all three MAPK pathways inhibited
TPA induction of RTA promoter reporter activities in a dose-
dependent fashion. At the highest doses, the ERK, JNK and p38
DNs inhibited the reporter activities by 82%, 84% and 82%,
respectively (Fig. 5C). Together, these results indicated that the
MAPK pathways were essential for TPA-induced activation of
the RTA promoter.
We further determined whether activation of each of the
MAPK pathways was sufficient to activate the RTA promoter.
Bjab cells were co-transfected with the RTA promoter reporter
with constitutively active constructs (CAs) of MAPK pathways,
and assayed for luciferase activities at 48 h post-transfection. As
shown in Fig. 5D, CAs of the ERK, JNK and p38 pathways
activated the RTA promoter reporter by 15.2-, 11.0- and 9.8-fold, respectively. Co-transfection with their respective DNs
abolished the activation of the RTA promote reporter by the
CAs (Fig. 5D). These results indicated that the MAPK pathways
were not only necessary but also sufficient for activating the
RTA promoter.
MAPK pathways modulated TPA activation of the RTA
promoter through AP-1
To map the region in the RTA promoter that mediated TPA
induction, we carried out reporter assays with a set of RTA
promoter serial deletion constructs. These deletion constructs
were previously used to map the responsive region during
KSHV productive primary infection in HUVEC (Pan et al.,
2006). As shown in Fig. 6A, the region from −15 to −259
contributed the most to TPA activation of the RTA promoter.
This region was also previously mapped to be responsive to the
modulation of MAPK pathways during KSHV primary
infection (Pan et al., 2006). Furthermore, an AP-1 site was
identified in this region as a target of the MAPK pathways
during KSHV primary infection (Pan et al., 2006). Based on our
current and previous findings, it appeared that the AP-1 site also
mediated the activation of the RTA promoter during TPA-
induced KSHV reactivation. Thus, we used the reporter R-259
and its mutant construct R-259mut with the AP-1 site mutated
to define the role of AP-1 in TPA-induced activation of the RTA
promoter (Fig. 6B). While TPA induced a 4.3-fold increase of
the wild-type R-259 reporter activity, mutation of the AP-1 site
totally abolished TPA induction of the mutant R-259mut
reporter activity (Fig. 6C). As expected, DNs of the MAPK
pathways reduced TPA activation of the R-259 reporter
activities (Fig. 6C). Specifically, DNs of the ERK, JNK and
p38 pathways reduced 100%, 70% and 59% of the reporter
activities, respectively. Similar results were obtained when
inhibitors of the MAPK pathways were used though the
inhibitory effects were slightly lower (Fig. 6D). The MEK, JNK
and p38 inhibitors reduced 61%, 59% and 49% of the R-259
reporter activities, respectively. Similar to the full-length RTA
reporter construct, activation of the MAPK pathways with CAs
also increased the activities of the R-259 reporter but not the
mutant R-259mut reporter (Fig. 6E). CAs of the ERK, JNK and
p38 pathways activated the R-259 reporter by 4.6-, 3-, and 2-
fold, respectively, which was inhibited by co-transfection with
their respective DNs (Fig. 6E).
Since mutation of the AP-1 site affected modulation of the
RTA promoter by the MAPK pathways, of which AP-1 is a
downstream target, we directly examined the role of AP-1 in the
regulation of TPA-induced activation of the RTA promoter. DNs
of either c-Fos or c-Jun reduced TPA activation of the R-259
reporter by 100% and 65%, respectively (Fig. 6F). In con-
sistency with these results, we have previously shown that
overexpression of CA of either c-Fos or c-Jun alone is sufficient
to activate the RTA promoter, which is inhibited by co-
transfection with their respective DNs (Pan et al., 2006). We
further conducted electrophoretic mobility shift assay (EMSA)
to examine the direct binding of the AP-1 protein complex to the
RTA promoter. As shown in Fig. 7, wild-type probe from the
146 J.P. Xie et al. / Virology 371 (2008) 139–154putative AP-1 site in the RTA promoter formed a DNA–protein
complex when nuclear extract of uninduced BCBL-1 cells was
used. The intensity of this complex was significantly increased
upon TPA induction. Competition with the unlabeled wild-type cold probe but not the mutant probe abolished the DNA–
protein complex. IgG of an antibody to c-Fos or c-Jun but
not that a control antibody supershifted the DNA–protein
complex, indicating that it was indeed an AP-1 complex. In
Fig. 5. TPA-induced activation of the RTA promoter was mediated by multiple MAPK pathways. (A) Kinetics of TPA activation of the RTA promoter reporter. Bjab
cells were transfected with a full-length RTA promoter reporter construct, and assayed for luciferase activity at 48 h post-transfection. Prior to harvest, cells were
treated with 20 ng/ml of TPA for 0, 1, 2, 4, 6, 8, 12, and 15 h. (B) Inhibitors of MAPK pathways suppressed TPA activation of the RTA promoter reporter in a dose-
dependent fashion. Bjab cells transfected with a RTA promoter reporter construct for 42 h were treated with 20 ng/ml of TPA for 6 h with or without inhibitors of JNK,
MEK and p38 pathways, lysed, and assayed for luciferase activity. The inhibitors were used at the following concentrations: JNK inhibitor II (JNK inhibitor) at 12.5,
25, 50 and 100 μM; U0126 (MEK inhibitor) at 2.5, 5, 10, and 20 μM; and SB203580 (p38 inhibitor) at 12.5, 25, 50 and 100 μM. (C) Dominant negative constructs
(DNs) of MAPK pathways inhibited TPA activation of the RTA promoter reporter in a dose-dependent fashion. Bjab cells transfected with a RTA promoter reporter
construct together with a vector control (V) or different doses of DNs of JNK, MEK and p38 MAPK pathways for 42 h were treated with TPA for 6 h, lysed, and
assayed for luciferase activity. (D) Overexpression of active forms (CAs) of ERK, JNK or p38 was sufficient to activate the RTA promoter, which was abolished by
their respective DNs. Bjab cells transfected with a RTA promoter reporter construct together with a vector control or a CA of ERK, JNK or p38 with or without the
presence of their respective DNs for 48 h were lysed and assayed for luciferase activity. The experiments were carried out three times, each with three repeats. Results
presented were the averages with standard deviations from one experiment.
147J.P. Xie et al. / Virology 371 (2008) 139–154contrast, the mutant probe did not form any AP-1 DNA–protein
complex with nuclear extracts from either uninduced or TPA-
induced BCBL-1 cells (Fig. 7). Together, these results clearly
demonstrated that MAPK pathways mediated the activation of
the RTA promoter through AP-1.Fig. 4. Inhibitors of MAPK pathways suppressed the expression of viral lytic genes durin
MAPK pathways suppressed the expression of KSHV lytic transcripts but not latent tran
inhibitors of MAPK pathways, and analyzed for the expression of vFLIP, RTA, ORF59, v
suppressed the protein expression of aKSHV lytic geneORF59duringKSHVreactivation
protein at 48 hpi by immunofluorescence antibody staining using a specific monoclonal
expression of ORF59 protein during KSHV reactivation as described in panel B. (D) Inh
LANA during KSHV reactivation. Cells were treated as described in panel A and analyz
staining using a specific monoclonal antibody. All the experiments were independently ca
were the averages with standard deviations from one representative experiment.Discussion
The mechanisms controlling KSHV lytic replication are
complex. Whether KSHV undergoes latent or lytic replication
might depend on multiple factors including: the status ofg TPA-induced KSHV reactivation from latency in BCBL-1 cells. (A) Inhibitors of
scripts during KSHV reactivation. Cells were induced with TPA in the presence of
IL-6 and K8.1 transcripts at 48 hpi by RT-qPCR. (B) Inhibitors of MAPK pathways
.Cellswere treated as described in panelA and analyzed for the expression ofORF59
antibody. (C) Quantification of the effects of inhibitors of MAPK pathways on the
ibitors of MAPK pathways had no effect on the expression of KSHV latent protein
ed for the expression of LANA protein at 48 hpi by immunofluorescence antibody
rried out three times, each with three repeats. Results presented in panel A, C and D
Fig. 6. Identification of the dominant cis-element in RTA promoter activated by TPA. (A) Deletion analysis of the RTA promoter to identify the region responsive to TPA induction. Bjab cells transfected with different RTA
promoter deletion reporter constructs for 42 h were treated with 20 ng/ml of TPA for 6 h, lysed, and assayed for luciferase activity. (B) Illustration of a wild type reporter (R-259) in the RTA promoter region (−15 to −259)
responsive to TPA induction. R-259mut was a corresponding mutant reporter with the AP-1 site ablated. (C) Dominant negative constructs (DNs) of MAPK pathways inhibited TPA activation of the R-259 reporter while the
mutant R-259mut reporter was not responsive to TPA treatment. Bjab cells transfected with R-259 or R-259mut reporter constructs together with a vector control (V) or DNs of the JNK,MEK and p38MAPK pathways for 42 h
were treated with TPA for 6 h, lysed and assayed for luciferase activity. (D) Inhibitors of MAPK pathways suppressed TPA activation of the R-259 reporter. Bjab cells transfected with R-259 or R-259mut reporter constructs for
42 hwere treated with 20 ng/ml of TPA for 6 hwith or without inhibitors of JNK,MEK and p38 pathways, lysed and assayed for luciferase activity. Both JNK inhibitor II (JNK inhibitor) and SB203580 (p38 inhibitor) were used
at 50 μM while U0126 (MEK inhibitor) was used at 10 μM. (E) Overexpression of an active form (CA) of ERK, JNK or p38 was sufficient to activate the R-259 reporter but not the mutant R-259mut reporter. Bjab cells
transfected with R-259 or R-259mut reporter constructs together with a vector control or a CA of ERK, JNK or p38with or without their respective DNs for 48 h were lysed and assayed for luciferase activity. (F) DN of c-Fos or
c-Jun inhibited TPA activation of the R-259 reporter. Bjab cells transfected with R-259 or R-259mut reporter constructs together with a vector control (V) or DN of c-Fos, c-Jun, or both for 42 h were treated with TPA for 6 h,
lysed and assayed for luciferase activity.
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Fig. 7. Increased binding of AP-1 complexes to a putative AP-1 cis-element in the
RTA promoter during TPA-induced KSHV reactivation from latency in BCBL-1
cells. Nuclear extracts fromuninduced cells (lanes 3–4) or cells inducedwith 20 ng/
ml of TPA for 6 h (lanes 5–16) were subjected to electrophoretic mobility shift
assay using a 32P-labeled probe of the putative AP-1 cis-element from the RTA
promoter (W) or its mutant with the putative AP-1 site mutated (M). The labeled
probes alone were shown in lanes 1 and 2, respectively. In the competition assay,
100× excess amounts of unlabeled probes were added to the reactions (lanes 7–10).
Addition of 1 μg of an antibody to c-Fos (lanes 11–12), or c-Jun (lanes 13–14),
respectively, supershifted theAP-1-probe complex, while addition of 1 μdfg of IgG
of a control antibody did not (lanes 15–16).
149J.P. Xie et al. / Virology 371 (2008) 139–154cellular signaling pathways, cell cycle, extracellular factors, cell
types, stages of viral infection, and the expression of viral
proteins. In this report, we have shown that the MEK/ERK,
JNK and p38 MAPK pathways regulate TPA-induced KSHV
reactivation from latency. These results are consistent with
those of KSHV productive primary infection (Pan et al., 2006).
Although KSHV lytic replication during productive primary
infection and reactivation from latency have similar as well as
distinct features, our previous and current studies have shown
that both processes are regulated by all three MAPK pathways.
These two studies have identified AP-1 as the downstream
target of the three MAPK pathways that mediates the expression
of RTA, the key transactivator of KSHV lytic replication, during
viral primary infection and reactivation from latency (Pan et al.,
2006). AP-1 also mediates TPA-induced expression of several
other KSHV lytic genes such as MTA (ORF57) and RAP (ORF-
K8) as well as the origins of lytic replication (oriLyts) (Byun
et al., 2002; AuCoin et al., 2004; Wang et al., 2004). Together,
these findings suggest that the MAPK pathways might have
general roles in regulating different stages/phases of KSHV life
cycle.
Several KSHV proteins and the binding of KSHV
glycoproteins to cellular receptors mediate the activation of
AP-1 and MAPK pathways. Two KSHV gene products, LANAand vFLIP, directly activate AP-1 (An et al., 2002, 2003, 2004).
vFLIP and five other KSHV gene products: vGPCR (ORF74),
vPK (ORF36), LAMP (ORF-K15), kaposin B (ORF-K12) and
ORF49, activate MAPK pathways (Akula et al., 2002; An et al.,
2003; Bais et al., 1998; Brinkmann et al., 2003; Hamza et al.,
2004; McCormick and Ganem, 2005; Xie et al., 2005; Gonzalez
et al., 2006). Some of these viral genes such as vGPCR, vPK
and ORF49 are viral lytic genes, and thus their expression could
lead to a positive feedback in viral lytic replication through the
activation of MAPK pathways; however, other viral genes such
as LANA and vFLIP are latent genes, and thus could activate
the AP-1 and MAPK pathways during KSHV latency. In fact,
we detected constitutive activation of all three MAPK pathways
in latent KSHV-infected BCBL-1 cells (Fig. 1). Constitutive
activation of both the JNK and p38 pathways in KSHV-infected
latent cells has not been reported before but has been shown for
the MEK/ERK pathway (Cohen et al., 2006; Ford et al., 2006).
It is unclear why the majority of the cells remain latent since
forcing activation of the MAPK pathways or AP-1 is sufficient
to activate the expression of RTA (Figs. 5D and 6E) (Pan et al.,
2006). There are several possible explanations. 1) There could
be thresholds of activated levels of these pathways that are
required for the activation of RTA and viral lytic replication. 2)
The activation of the downstream targets by MAPK pathways
could vary during viral latency and reactivation, some of which
could have favorable while others could have repressive effects
on viral lytic replication. For example, the AP-1 complexes
could be formed by different components including c-Fos,
FosB, c-Jun, JunB, JunD, Fra-1 and Fra-2, some of which have
positive while others have repressive effects on gene expression
(Shaulian and Karin, 2002). While KSHVactivates the positive
regulators of MAPK pathways, including c-Jun, c-Fos and FosB
during primary infection (Xie et al., 2005), it remains to be
determined what components of AP-1 are activated during
KSHV latency and reactivation. 3) LANA also has repressive
functions for KSHV lytic replication. Binding of LANA to the
episome results in epigenetic modifications of the viral genomes
and repression of gene expression (Sakakibara et al., 2004; Lan
et al., 2005; Lu et al., 2006). In addition, LANA binds to RTA
and its promoter to repress its expression and transactivation
function (Lan et al., 2004, 2005). 4) Other viral, host and
environmental factors could play synergetic or opposing effects
on KSHV lytic replication. Therefore, further defining the
interactions of MAPK pathways with other viral, host and
environmental factors during KSHV lytic replication could shed
light on the molecular basis of KSHV life cycle. In this case, the
application of reverse genetics approach to define the viral cis-
element(s) responsive to MAPK pathways or the AP-1, or viral
factors that could mediate these pathways would be particularly
insightful (Zhou et al., 2002).
The identification of MAPK pathways and the downstream
target AP-1 as important regulators of KSHV lytic replication is
of particular interest. A number of inflammatory and angiogenic
cytokines including: IL-6, bFGF, TNF-α, interferon-γ, VEGF,
oncostatin M, and IL-1β are expressed in KS tumors (Ensoli
et al., 2001a,b), and regulate MAPK pathways (Chaturvedi and
Sarkar, 2005; Kang et al., 2005; Kaplin et al., 2005; Weiss et al.,
150 J.P. Xie et al. / Virology 371 (2008) 139–1542005; Aoki et al., 2006; Boing et al., 2006; Lee et al., 2006).
Thus, some of these cytokines could modulate KSHV
reactivation. In fact, several inflammatory cytokines are capable
of reactivating KSHV. Interferon-γ reactivates KSHV lytic
replication and the expression of lytic genes in PEL cells and
peripheral blood mononuclear cells isolated from KS patients
(Monini et al., 1999; Blackbourn et al., 2000; Chang et al.,
2000; Mercader et al., 2000). Oncostatin M also induces KSHV
lytic replication in BCBL-1 cells (Mercader et al., 2000). We
have previously shown that MAPK pathways modulate KSHV
infectivity and subsequent productive lytic replication during
KSHV primary infection (Pan et al., 2006). Thus, besides viral
lytic replication, inflammatory and angiogenic cytokines can
also modulate KSHV infectivity. Indeed, it was recently
demonstrated that VEGF induced by Raf enhances KSHV
infectivity (Hamden et al., 2004). It could be postulated that such
VEGF-mediated enhancement of KSHV infectivity could be via
the activation of MAPK pathways. Importantly, the expression
of many inflammatory and angiogenic cytokines is also
modulated by MAPK pathways and AP-1, which could have a
positive feedback on KSHV lytic replication and infection (Xie
et al., 2005; Ye et al., 2007; Qian et al., 2007). Therefore, as we
have postulated (Xie et al., 2005), a sustaining reactivation and
productive primary infection cycle in the host could contribute
to the rapid progression of KS by not only producing large
quantities of virions for infecting new cells but also contributing
to other aspects of KS pathogenesis, including the production
of inflammatory and angiogenic cytokines, and promotion of
cellular transformation, cell invasion and angiogenesis.
Materials and methods
Plasmids
The full-length RTA promoter reporter construct, R-914 and
its consecutive deletion constructs R-836, R-587, R-348, R-259
and R-15 were previously described (Pan et al., 2006). A mutant
construct of the R-259 reporter, R-259mut, with the putative
AP-1 site mutated from (−87)-CGACTCA-(−81) to (−87)-
CGGATCC-(−81) was also used in the study. The following
plasmids were previously described: pCEP4L-ERK1 and
pCEP4L-HA-ERK1K71R are expression vectors for ERK1
and its DN, respectively (Frost et al., 1994); pcDNA3-wt-p38 is
an expression vector for wild-type p38 (Thomas et al., 2002);
pcDNA3-p38/AF is a DN of p38 (Han et al., 1995); HA-JNK/
pCAGGGS is a JNK1 expression construct with JNK1 cloned
into the pCAGGS vector (Fujii et al., 2004). HA-JNK[APF] is a
DN of JNK (Derijard et al., 1994); A-Fos is a DN of c-Fos
(Olive et al., 1997); pcDNA3Flag-c-Fos expresses an active
form of c-Fos (Murphy et al., 2002); and RSV-c-Jun expresses
an active form of c-Jun (Kim et al., 2003). DN-c-Jun is a DN
construct of c-Jun construct (Pan et al., 2006).
Cell culture
BCBL-1 cells harboring a recombinant KSHV, BAC36, have
been previously described (Zhou et al., 2002). BCBL-1 cellswere cultured in RPMI1640 medium supplemented with 10%
fetal bovine serum (FBS, Sigma, St. Louis, MO), 50 μg/ml of
gentamicin, and 2 mM L-glutamine. For virus titration, 293 cells
were used as target cells, and were cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10%
FBS, 50 μg/ml of gentamicin, and 2 mM L-glutamine.
Virus induction and titration
Virus induction and titration were carried out as described
previously (Zhou et al., 2002; Gao et al., 2003). To induce
KSHV lytic replication, BCBL-1 cells were treated with 20 ng/
ml of TPA (Sigma) for different lengths of time depending on
the experiments. In some experiments, specific inhibitors were
used to inhibit the MAPK pathways. The inhibitors were U0126
for MEK, JNK Inhibitor II for JNK, and SB 203580 for p38, all
purchased from Calbiochem (EMD Biosciences, Inc., San
Diego, CA). Inhibitors were freshly reconstituted at 1000× of
their recommended concentrations (10 μM for U0126, and
50 μM for both JNK Inhibitor II and SB203580) with dimethyl
sulfoxide before use. The inhibitors were used at 1× of their
recommended concentrations unless specified.
For virus titration, 293 cells at 60–70% confluency seeded in
a 96-well plate 1 day before were infected with culture
supernatants or virus inocula at 50 μl/well in the presence of
4 μg/ml of polybrene, and incubated at 37 °C for 4 h. The viral
inoculum was then removed and replaced with normal culture
medium. The plates were examined with an inverted fluores-
cence microscope at 48 h post-infection for the percentage of
cells expressing GFP, which was then converted to GFU to
reflect the virus titer in the inoculum. For each treatment, virus
titration was carried out in 4 wells. The number of GFP-positive
cells for each well was obtained by averaging the results of 9
microscopic fields randomly selected with a 20× objective. In
all the experiments involving the use of inhibitors to determine
the relevance of the MAPK pathways in KSHV reactivation, the
inocula were titrated at day 5 after the addition of the inhibitors
to ensure that they no longer interfered with virus infectivity
(see Fig. 2C).
Western-blot analysis
Protein preparations from BCBL-1 cells were separated by
SDS-polyacrylamide gel electrophoresis (PAGE), and trans-
ferred to nitrocellulose membranes as previously described
(Gao et al., 1996a). The membranes were incubated first with
antibodies specific for phosphorylated forms of ERK, JNK,
and p38, respectively (Santa Cruz Biotechnology, Santa Cruz,
CA), and then with a goat anti-rabbit horseradish peroxidase
(HRP) conjugate (Sigma). Antibodies specific to total ERK,
JNK and p38 were used to detect the expression of the
respective proteins (Santa Cruz Biotechnology). A mouse
antibody to β-tubulin (Sigma) was used to monitor sample
loading. Specific signals were revealed with chemilumines-
cence substrates, and recorded on films or with a Kodak Image
Station 2000 MM Multi-Modal Imager (Eastman Kodak
Company, Rochester, NY).
151J.P. Xie et al. / Virology 371 (2008) 139–154RNA extraction and reverse transcription quantitative real-time
PCR (RT-qPCR)
RT-qPCR was performed as previously described (Yoo et al.,
2005). Briefly, total RNA from BCBL-1 was prepared with TRI
reagent as recommended by the manufacturer (Sigma). The
RNA was treated with RQ1 RNase-free DNase (Promega,
Madison, WI) and reverse transcribed to obtain the first-strand
cDNA using a Superscript III first-stand synthesis system
(Invitrogen, Carlsbad, CA). qPCR was carried out in a DNA
engine Opiticon 2 continuous fluorescence detector (Bio-Rad,
Hercules, CA). PCR was also carried out on the RNA samples
without reverse transcription to exclude any possible genomic
DNA contamination. The vFLIP primers were 5′GGATGCCC-
TAATGTCAATGC3′ (forward) and 5′GGCGATAGTGTTGG-
GAGTGT3′ (reverse), which amplified a product of 113 bp.
The RTA primers were 5′CACAAAAATGGCGCAAGAT-
GA3′ (forward) and 5′TGGTAGAGTTGGGCCTTCAGTT3′
(reverse), which amplified a product of 98 bp. The ORF59
primers were 5′CGAGTCTTCGCAAAAGGTTC3′ (forward)
and 5′AAGGGACCAACTGGTGTGAG3′ (reverse), which
amplified a product of 99 bp. The vIL-6 primers were 5′AC-
CCTTGCAGATGCCGG3′ (forward) and 5′GGATGCTA-
TGGGTGATCGATG3′ (reverse), which amplified a product
of 65 bp. The ORF-K8.1 primers were 5′AAAGCGTCCAGGC-
CACCACAGA3′ (forward) and 5′GGCAGAAAATGGCAC-
ACGGTTAC3′ (reverse), which amplified a product of 160 bp.
Primers for glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) GAPDH-F (5′ACAGTCAGCCGCATCTTCTT3′)
and GAPDH-R (5′ACGACCAAATCCGTTGACTC3′) that
amplify a product of 94 bp were used to normalize the samples.
Each sample was assayed with three repeats.
Immunofluorescence antibody assay (IFA)
IFAwas carried out as previously described to determine the
protein expression of ORF59 (Gao et al., 1996b). Briefly,
BCBL-1 cells were washed 3 times with PBS by centrifugation
and evenly spread onto 10-well slides. After fixation at 56 °C
for 1 h, the slides were blocked with 3% bovine serum albumin
(BSA) in PBS. The slides were incubated with a mouse anti-
ORF59 monoclonal antibody kindly provided by Dr. Bala
Chandran (Chan et al., 1998). Specific signals were revealed
with a goat anti-mouse IgG-ALEXA568 conjugate (Molecular
Probe, Eugene, OR). To detect LANA protein, a rat-anti-LANA
monoclonal antibody (ABI, New York, NY) was used. A goat
anti-rat IgG-ALEXA568 conjugate was used to reveal the
specific signal. The cells were stained with DAPI at 1 μg/ml for
1 min at room temperature, and analyzed with a digitalized
Zeiss fluorescent microscope.
Transient transfection and reporter assay
Transient transfection and reporter assays were carried out
in Bjab cells. Cells (1×107) were harvested and used for
Nucleofection electroporation using Nucleofator® Solution V
according to the instructions of the manufacturer (Amaxa Inc.,Gaithersburg, MD). To control the transfection efficiency,
samples were normalized by cotransfection with a reporter
plasmid, pSV-β-galactosidase (Promega). The cells were
collected in 300 μl of 1× lysis buffer (Promega) at 48 h after
transfection. An aliquot of the supernatant (60 μl) and a
β-galactosidase kit (Promega) were used to measure the
β-galactosidase activity. All the reporter assays were indepen-
dently carried out three times with three repeats each time.
Electrophoretic mobility shift assay (EMSA)
EMSAwas carried out with nuclear extracts from uninduced
or TPA-induced BCBL-1 cells as previously described (Wang
et al., 2002). Annealed double-stranded oligonucleotides (5′-
GGGAGCTACCGGCGACTCATTAAGC3′) from the putative
AP-1 site in the RTA promoter and its mutant (5′GGGAGC-
TACCGGCGGATCCTTAAGC3′) with the mutated positions
underlined were labeled with [γ-32P]ATP. For gel shift assays,
4 μg of nuclear extract was incubated for 20 min at room
temperature with 5×105 cpm of the labeled probe in 20 μl of
binding buffer, containing 10 mM Tris–HCl at pH 7.6, 50 mM
NaCl, 1 mM EDTA, 1 mM DTT, 5% glycerol, 1 μg/μl of BSA,
and 2 μg of poly-d(I–C). Competition assays were carried out in
the same manner except that the above reaction mixture was pre-
incubated with excess cold wild-type or mutant probe for 10 min
at 4 °C before the addition of the labeled probe. For antibody
supershift assays, 2 μg of an antibody to either c-Fos or c-Jun
(Santa Cruz) was added to the reactions. Samples were separated
on 6% non-denaturing PAGE.
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